2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.10 Grant

PP01.10 Grant - Poster

Pdf Summary

The study evaluates the effectiveness of afatinib in patients with non-small cell lung cancer (NSCLC) who have a rare EGFR exon 19 deletion mutation, L747_A750delinsP, through a pooled analysis of various clinical trials. While the common EGFR mutation E746_A750del is well understood and treated with pan-TKI therapy, little is known about the uncommon EGFR exon 19 deletions. The research suggests that afatinib, a 2nd generation TKI, may be more effective in targeting the L747_A750delinsP mutation compared to osimertinib. The results indicate that clinical outcomes, including response rates and progression-free survival, were similar for patients with common and uncommon EGFR mutations when treated with afatinib. However, further prospective studies are needed to compare afatinib with osimertinib specifically for patients with L747_A750delinsP tumors. The study emphasizes the potential role of afatinib as the preferred TKI for patients with NSCLC harboring the L747_A750delinsP mutation, consistent with preclinical and clinical findings. Overall, the results suggest that afatinib could be a promising treatment option for patients with tumors carrying this rare EGFR mutation.

Keywords

afatinib

non-small cell lung cancer

NSCLC

EGFR exon 19 deletion

L747_A750delinsP mutation

pooled analysis

2nd generation TKI

osimertinib

response rates

progression-free survival